Harvard Bioscience, Inc. (HBIO) has approved a 1‑for‑10 reverse stock split of its common stock, a move designed to lift the per‑share price above Nasdaq’s $1 minimum bid requirement and preserve the company’s listing on the Nasdaq Capital Market.
The split will take effect at 4:30 p.m. Eastern Time on March 13, 2026, reducing the number of shares outstanding from roughly 44.7 million to about 4.5 million. Shareholders who would receive a fractional share after the split will be paid cash equal to the fractional amount multiplied by the closing price on the effective date. The company will also adjust the exercise and conversion prices of all outstanding options, warrants, and convertible securities to reflect the new share count.
The reverse split comes amid a period of financial distress for HBIO. In the first quarter of 2025, the company reported revenue of $21.8 million, down 11.2 % from the same period in 2024, and a net loss of $50.3 million, largely driven by a $48 million goodwill impairment charge. In the third quarter of 2025, revenue fell to $20.6 million and the net loss narrowed to $1.2 million, while gross margins expanded to 58.4 %. Adjusted EBITDA rose 27 % year‑over‑year to $3.8 million. The company’s balance sheet remains highly leveraged, with total debt of $33.967 million against shareholder equity of $14.068 million, giving a debt‑to‑equity ratio of 2.75 and an Altman Z‑Score of –4.69, a clear indicator of financial distress.
Management has outlined a strategy to address these challenges. CEO John Duke has emphasized financial discipline, accelerating adoption of core growth products, and strengthening the capital structure through debt refinancing. The company secured a $40 million credit facility in December 2025 to repay existing debt and extend maturities, and it has closed its Holliston, Massachusetts manufacturing facility as part of a broader consolidation effort aimed at reducing operating costs.
HBIO’s Nasdaq compliance history underscores the urgency of the reverse split. The company received a delisting extension until March 30, 2026 after being notified of non‑compliance with the $1 minimum bid requirement in April 2025. It transferred its listing to the Nasdaq Capital Market on October 3, 2025, a move that lowered the minimum bid requirement but still required the share price to remain above $1. The reverse split is therefore a tactical measure to meet the bid price threshold while the company works to improve its financial fundamentals.
While the reverse split will temporarily raise the per‑share price, it does not resolve the underlying issues that have driven HBIO’s revenue decline, net losses, and high leverage. Investors will likely view the split as a stopgap measure, and the company’s continued focus on cost discipline, product adoption, and debt reduction will be critical to restoring long‑term financial health and investor confidence.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.